{"id":9250,"date":"2015-07-24T18:29:28","date_gmt":"2015-07-24T18:29:28","guid":{"rendered":"http:\/\/admin.acceleratingscience.com\/behindthebench\/?p=9250"},"modified":"2020-05-28T19:19:36","modified_gmt":"2020-05-28T19:19:36","slug":"finding-the-bcr-abl-fusion-gene-in-the-haystack","status":"publish","type":"post","link":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/finding-the-bcr-abl-fusion-gene-in-the-haystack\/","title":{"rendered":"Finding The BCR-ABL Fusion Gene In The Haystack"},"content":{"rendered":"

When it comes to quantifying molecular targets in chronic myeloid leukemia<\/a> (CML) samples, Real-time PCR<\/a> has long been trusted as the gold standard. However, new research is showing that digital PCR<\/a> holds new promise in two key areas: increased sensitivity and absolute quantification.<\/p>\n

As Mary Alikian from Imperial College London<\/a> explains in the latest LabChat<\/a>, real-time PCR presents the challenge of quantification using standard curves, which always made it difficult for different labs to compare their data. On top of eliminating the need for standard curves, digital PCR also allows for deeper quantification amidst a background of wild types. According to Mary, quantification can feasibly increase from 1 in a 100,000 to 1 in a 1,000,000 using digital PCR.<\/p>\n